Dipeptidyl peptidase-4: A key player in chronic liver disease

World Journal of Gastroenterology

Volumn 19, Issue 15, 2013, Pages 2298-2306

  Itou, Minoru ^a   Kawaguchi, Takumi ^a   Taniguchi, Eitaro ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alogliptin; Cancer; Incretin; Insulin resistance; Linagliptin; Sitagliptin; Steatohepatitis; Teneligliptin; Vildagliptin; Viral hepatitis

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; COLLAGEN TYPE 4; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INCRETIN; INTERFERON; INTERLEUKIN 12; METALLOPROTEINASE; NEUROPEPTIDE; PEPTIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SITAGLIPTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DRUG BINDING; DRUG DEGRADATION; DRUG DISTRIBUTION; EXTRACELLULAR MATRIX; FOOD INTAKE; GLUCOSE METABOLISM; HEMATOPOIETIC STEM CELL; HEPATITIS C; HOMEOSTASIS; HUMAN; IMMUNOSTIMULATION; INSULIN RESISTANCE; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLEIOTROPY; REVIEW; TISSUE DISTRIBUTION;

EID: 84876523499     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i15.2298     Document Type: Review

References (136)

1. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966; 7: 197-201 [PMID: 5959122 DOI: 10.1007/ BF00577838]
2. Misumi Y, Hayashi Y, Arakawa F, Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1992; 1131: 333-336 [PMID: 1352704 DOI: 10.101 6/0167-4781(92)90036-Y]
3. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466-469 [PMID: 8101391 DOI: 10.1126/science.8101391]
4. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993; 177: 1135-1143 [PMID: 8096237 DOI: 10.1084/ jem.177.4.1135]
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705 [PMID: 17098089 DOI: 10.1016/S0140-6736(06)69705-5]
6. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253-260 [PMID: 16416146 DOI: 10.1007/s00125-005-0107-1]
7. McCaughan GW, Gorrell MD, Bishop GA, Abbott CA, Shackel NA, McGuinness PH, Levy MT, Sharland AF, Bowen DG, Yu D, Slaitini L, Church WB, Napoli J. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev 2000; 174: 172-191 [PMID: 10807516 DOI: 10.1034/ j.1600-0528.2002.017420.x]
8. Mentzel S, Dijkman HB, Van Son JP, Koene RA, Assmann KJ. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 1996; 44: 445-461 [PMID: 8627002 DOI: 10.1177/44.5.8627002]
9. Kikuchi M, Fukuyama K, Epstein WL. Soluble dipeptidyl peptidase IV from terminal differentiated rat epidermal cells: purification and its activity on synthetic and natural peptides. Arch Biochem Biophys 1988; 266: 369-376 [PMID: 2461166 DOI: 10.1016/0003-9861(88)90268-8]
10. Heike M, Möbius U, Knuth A, Meuer S, Meyer zum Büschenfelde KH. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol 1988; 74: 431-434 [PMID: 2466591]
11. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-264 [PMID: 11555388 DOI: 10.1046/j.1365-3083.2001.00984.x]
12. Dinjens WN, Ten Kate J, Wijnen JT, van der Linden EP, Beek CJ, Lenders MH, Khan PM, Bosman FT. Distribution of adenosine deaminase-complexing protein in murine tissues. J Biol Chem 1989; 264: 19215-19220 [PMID: 2681214]
13. Moody DE, Taylor LA, Smuckler EA. Immunofluorescent determination of the lobular distribution of a constitutive form of hepatic microsomal cytochrome P-450. Hepatology 1985; 5: 440-451 [PMID: 3888809 DOI: 10.1002/ hep.1840050317]
14. Irie M, Suzuki N, Sohda T, Anan A, Iwata K, Takeyama Y, Watanabe H, Fischer P, Scherberich JE, Sakisaka S. Hepatic expression of gamma-glutamyltranspeptidase in the human liver of patients with alcoholic liver disease. Hepatol Res 2007; 37: 966-973 [PMID: 17854466 DOI: 10.1111/j.1872-034X.2007.00151.x]
15. Häussinger D, Gerok W. Hepatocyte heterogeneity in glutamate uptake by isolated perfused rat liver. Eur J Biochem 1983; 136: 421-425 [PMID: 6414814 DOI: 10.1111/ j.1432-1033.1983.tb07759.x]
16. Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL. Ta1, a novel 105. KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984; 133: 1250-1256 [PMID: 6205075]
17. Hegen M, Niedobitek G, Klein CE, Stein H, Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990; 144: 2908-2914 [PMID: 1969875]
18. Yamabe T, Takakura K, Sugie K, Kitaoka Y, Takeda S, Okubo Y, Teshigawara K, Yodoi J, Hori T. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997; 91: 151-158 [PMID: 9203979 DOI: 10.1046/ j.1365-2567.1997.00230.x]
19. Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008; 13: 2299-2310 [PMID: 17981712 DOI: 10.2741/2844]
20. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16: 2943-2951 [PMID: 19689275 DOI: 10.2174 /092986709788803114]
21. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H, Dang NH, Morimoto C. CD26 up-regulates expression of CD86 on antigenpresenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004; 101: 14186-14191 [PMID: 15353589 DOI: 10.1073/ pnas.0405266101]
22. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007; 282: 10117-10131 [PMID: 17287217 DOI: 10.1074/jbc.M609157200]
23. Piazza GA, Callanan HM, Mowery J, Hixson DC. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem J 1989; 262: 327-334 [PMID: 2573346]
24. Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003; 278: 24600-24607 [PMID: 12716896 DOI: 10.1074/jbc.M303424200]
25. Walborg EF, Tsuchida S, Weeden DS, Thomas MW, Barrick A, McEntire KD, Allison JP, Hixson DC. Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res 1985; 158: 509-518 [PMID: 3891389 DOI: 10.1016/0014-4827(85)90474-4]
26. Löster K, Zeilinger K, Schuppan D, Reutter W. The cysteinerich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 1995; 217: 341-348 [PMID: 8526932 DOI: 10.1006/bbrc.1995.2782]
27. Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 2006; 12: 3470-3477 [PMID: 16740772 DOI: 10.1158/1078-0432. CCR-06-0361]
28. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005; 65: 1325-1334 [PMID: 15735018 DOI: 10.1158/0008-5472.CAN-04-1852]
29. Gonzalez-Gronow M, Hershfield MS, Arredondo-Vega FX, Pizzo SV. Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. J Biol Chem 2004; 279: 20993-20998 [PMID: 15016824 DOI: 10.1074/jbc.M401023200]
30. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005; 108: 277-292 [PMID: 15584901 DOI: 10.1042/CS20040302]
31. Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, Dang NH. CD26 regulates p38 mitogenactivated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 2005; 65: 6950-6956 [PMID: 16061680 DOI: 10.1158/0008-5472.CAN-05-0647]
32. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007; 13: 4191-4200 [PMID: 17634548 DOI: 10.1158/1078-0432.CCR-07-0110]
33. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825-6830 [PMID: 12748388 DOI: 10.1073/ pnas.0631828100]
34. Eggstein S, Kreisel W, Gerok W, Eggstein M. [Dipeptidyl aminopeptidase IV in hospitalized patients and in galactosamine hepatitis of the rat: Activity and lectin affinity chromatography in serum and hepatic plasma membranes]. J Clin Chem Clin Biochem 1989; 27: 547-554 [PMID: 2575117]
35. Nilius R, Stuhec K, Dietrich R. Changes of dipeptidylpeptidase IV as a membrane marker of lymphocytes in acute and chronic liver diseases--biochemical and cytochemical investigations. Physiol Res 1991; 40: 95-102 [PMID: 1681896]
36. Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992; 15: 1048-1053 [PMID: 1350563 DOI: 10.1002/hep.1840150613]
37. Grüngreiff K, Hebell T, Gutensohn K, Reinhold A, Reinhold D. Plasma concentrations of zinc, copper, interleukin-6 and interferon-γ, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C. Mol Med Report 2009; 2: 63-68 [PMID: 21475791 DOI: 10.3892/mmr_00000062]
38. Itou M, Kawaguchi T, Taniguchi E, Sumie S, Oriishi T, Mitsuyama K, Tsuruta O, Ueno T, Sata M. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol 2008; 23: 244-251 [PMID: 17944883 DOI: 10.1111/ j.1440-1746.2007.05183.x]
39. Bonacini M, Govindarajan S, Kohla M, Lai MM, Lindsay KL. Intrahepatic lymphocyte phenotypes in hepatitis C virus infection: a comparison between cirrhotic and non-cirrhotic livers. Minerva Gastroenterol Dietol 2007; 53: 1-7 [PMID: 17415341]
40. Dimitropoulou D, Karakantza M, Tsamandas AC, Mouzaki A, Theodorou G, Gogos CA. T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C. In Vivo 2011; 25: 833-840 [PMID: 21753143]
41. Rahman W, Huang P, Belov L, Chrisp JS, Christopherson RI, Stapelberg PM, Warner FJ, George J, Bowen DG, Strasser SI, Koorey D, Sharland AF, McCaughan GW, Shackel NA. Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver Int 2012; 32: 1527-1534 [PMID: 22863037 DOI: 10.1111/j.1478-3231.2012.02854.x]
42. Sakata M, Kawahara A, Kawaguchi T, Akiba J, Taira T, Taniguchi E, Abe M, Koga H, Kage M, Sata M. Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens. J Gastroenterol 2013; 48: 277-285 [PMID: 22790351 DOI: 10.1007/s00535-012-0633-9]
43. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, Imaizumi T, Sata M. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol 2013; 48: 93-100 [PMID: 22678465 DOI: 10.1007/s00535-012-0610-3]
44. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat 2011; 18: 675-684 [PMID: 21914084 DOI: 10.1111/ j.1365-2893.2011.01474.x]
45. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305 [PMID: 21623851 DOI: 10.1111/j.1365-2036.2011.04716.x]
46. Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, Nakano M, Kawaguchi T, Ide T, Torimura T, Sata M. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res 2010; 40: 911-922 [PMID: 20887596 DOI: 10.1111/j.1872-034X.2010.00699.x]
47. Kawaguchi T, Taniguchi E, Itou M, Sumie S, Yamagishi S, Sata M. The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials 2010; 5: 147-157 [PMID: 20482494 DOI: 10.2174/157488710792007257]
48. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol 2010; 16: 1943-1952 [PMID: 20419831 DOI: 10.3748/wjg.v16.i16.1943]
49. Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K, Taniguchi E, Ando E, Takata A, Fukushima N, Koga H, Torimura T, Kojiro M, Sata M. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 2007; 18: 545-552 [PMID: 17671700]
50. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576 [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x]
51. Kawaguchi T, Nagao Y, Tanaka K, Ide T, Harada M, Kumashiro R, Sata M. Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study. Int J Mol Med 2005; 16: 109-114 [PMID: 15942686]
52. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508 [PMID: 15509521 DOI: 10.1016/S0002-9440(10)63408-6]
53. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848 [PMID: 14988838]
54. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171 [PMID: 17465001 DOI: 10.1002/ hep.21634]
55. Harada T, Kim DW, Sagawa K, Suzuki T, Takahashi K, Saito I, Matsuura Y, Miyamura T. Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J Gen Virol 1995; 76 (Pt 5): 1215-1221 [PMID: 7730805]
56. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001; 6: 475-480 [PMID: 11443537 DOI: 10.1038/sj.mp.4000872]
57. Lee S, Macquillan GC, Keane NM, Flexman J, Jeffrey GP, French MA, Brochier J, Price P. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol Cell Biol 2002; 80: 391-397 [PMID: 12121229 DOI: 10.1046/ j.1440-1711.2002.01102.x]
58. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 2002; 186: 1498-1502 [PMID: 12404169 DOI: 10.1086/344892]
59. Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 2003; 27: 59-68 [PMID: 12727530 DOI: 10.1016/ S1386-6532(02)00128-2]
60. Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand 2004; 109: 126-131 [PMID: 14725594 DOI: 10.1046/j.0001-690X.2003.00230.x]
61. Yang SS, Fu LS, Chang CS, Yeh HZ, Chen GH, Kao JH. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 1789-1793 [PMID: 17074015 DOI: 10.1111/j.1440-1746.2006.04677.x]
62. Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kobayashi T. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011; 41: 524-529 [PMID: 21435130 DOI: 10.1111/j.1872-034X.2011.00798.x]
63. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10.5754/hge11263]
64. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-268 [PMID: 20842510 DOI: 10.1007/ s00535-010-0305-6]
65. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595 [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z]
66. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2 [PMID: 22221544 DOI: 10.1186/1471-230X-12-2]
67. Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K, Takayanagi R. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 2012; 5: 729-733 [PMID: 22179204 DOI: 10.3892/mmr.2011.707]
68. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6: 242-250 [PMID: 18007554]
69. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagonlike peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011; 54: 1214-1223 [PMID: 21145820 DOI: 10.1016/j.jhep.2010.09.032]
70. Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K, Somogyi A. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010; 5: e12226 [PMID: 20805868 DOI: 10.1371/journal.pone.0012226]
71. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-1257 [PMID: 21330637 DOI: 10.2337/db10-1338]
72. Itou M, Kawaguchi T, Taniguchi E, Oriishi T, Sata M. Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. Case Rep Gastroenterol 2012; 6: 538-544 [PMID: 22949894 DOI: 10.1159/000341510]
73. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75: 240-244 [PMID: 22870790]
74. Leccia F, Nardone A, Corvigno S, Vecchio LD, De Placido S, Salvatore F, Veneziani BM. Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. Cytometry A 2012; 81: 960-972 [PMID: 22791584 DOI: 10.1002/cyto.a.22095]
75. Wilson CH, Abbott CA. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol 2012; 41: 919-932 [PMID: 22736146 DOI: 10.3892/ ijo.2012.1522]
76. Mareš V, Stremeňová J, Lisá V, Kozáková H, Marek J, Syrůček M, Šoula O, Šedo A. Compartment-and malignance-dependent up-regulation of γ-glutamyltranspeptidase and dipetidylpeptidase-IV activity in human brain gliomas. Histol Histopathol 2012; 27: 931-940 [PMID: 22648548]
77. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 2012; 18: 1447-1456 [PMID: 22261805 DOI: 10.1158/1078-0432. CCR-11-1990]
78. Starska K, Głowacka E, Kulig A, Lewy-Trenda I, Bryś M, Lewkowicz P. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I. Folia Histochem Cytobiol 2011; 49: 579-592 [PMID: 22252752 DOI: 10.5603/FHC.2011.0081]
79. McCaughan GW, Siah CL, Abbott C, Wickson J, Ballesteros M, Bishop GA. Dipeptidyl peptidase IV is down-regulated in rat hepatoma cells at the mRNA level. J Gastroenterol Hepatol 1993; 8: 142-145 [PMID: 8097118 DOI: 10.1111/ j.1440-1746.1993.tb01505.x]
80. Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/ CD26) expression in human hepatocellular carcinoma. J Hepatol 1997; 27: 337-345 [PMID: 9288609 DOI: 10.1016/ S0168-8278(97)80180-8]
81. Gaetaniello L, Fiore M, de Filippo S, Pozzi N, Tamasi S, Pignata C. Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells. Hepatology 1998; 27: 934-942 [PMID: 9537431 DOI: 10.1002/hep.510270407]
82. Yamamoto S, Tokuhara T, Nishikawa M, Nishizawa S, Nishioka T, Nozawa A, Takahashi A, Watanabe Y, Wada R, Wakasa K, Kubo S. Spontaneous regression of hepatocellular carcinoma after improving diabetes mellitus: possiblly responsible for immune system. Kanzo 2012; 53: 164-167
83. Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010; 30: 479-486 [PMID: 20040053 DOI: 10.1111/ j.1478-3231.2009.02191.x]
84. Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 2012; 179: 91-100 [PMID: 22989472 DOI: 10.1016/ j.regpep.2012.08.016]
85. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29: 1768-1778 [PMID: 10347120 DOI: 10.1002/hep.510290631]
86. Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet 2000; 27: 241-249 [PMID: 10998089]
87. Lee JH, Park HJ, Kim YA, Lee DH, Noh JK, Kwon CH, Jung SM, Lee SK. The phenotypic characteristic of liverderived stem cells from adult human deceased donor liver. Transplant Proc 2012; 44: 1110-1112 [PMID: 22564638 DOI: 10.1016/j.transproceed.2012.02.020]
88. Mavier P, Martin N, Couchie D, Préaux AM, Laperche Y, Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol 2004; 165: 1969-1977 [PMID: 15579440 DOI: 10.1016/S0002-9440(10)63248-8]
89. Zheng D, Oh SH, Jung Y, Petersen BE. Oval cell response in 2-acetylaminofluorene/partial hepatectomy rat is attenuated by short interfering RNA targeted to stromal cell-derived factor-1. Am J Pathol 2006; 169: 2066-2074 [PMID: 17148669 DOI: 10.2353/ajpath.2006.060211]
90. Ishikawa T, Factor VM, Marquardt JU, Raggi C, Seo D, Kitade M, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 2012; 55: 1215-1226 [PMID: 22095660 DOI: 10.1002/hep.24796]
91. Tsuchiya A, Imai M, Kamimura H, Takamura M, Yamagiwa S, Sugiyama T, Nomoto M, Heike T, Nagasawa T, Nakahata T, Aoyagi Y. Increased susceptibility to severe chronic liver damage in CXCR4 conditional knock-out mice. Dig Dis Sci 2012; 57: 2892-2900 [PMID: 22674400 DOI: 10.1007/ s10620-012-2239-8]
92. Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci 2008; 13: 1795-1805 [PMID: 17981668 DOI: 10.2741/2800]
93. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 2012; 41: 1166-1173 [PMID: 22219460 DOI: 10.1093/ejcts/ezr180]
94. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835 [PMID: 8100523 DOI: 10.1111/ j.1432-1033.1993.tb17986.x]
95. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagonlike peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957 [PMID: 7883856 DOI: 10.1210/jc.80.3.952]
96. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363 [PMID: 10537167 DOI: 10.1210/en.140.11.5356]
97. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8: 179-188 [PMID: 12529935 DOI: 10.1080/10606820213687]
98. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581 [PMID: 11061504 DOI: 10.1210/jc.85.10.3575]
99. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50: 1588-1597 [PMID: 11423480 DOI: 10.2337/diabetes. 50.7.1588]
100. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 2006; 16: 651-658 [PMID: 16687037 DOI: 10.1381/096089206776944959]
101. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006; 16: 795-803 [PMID: 16756746 DOI: 10.1381/096089206777346619]
102. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418-22423 [PMID: 12690116 DOI: 10.1074/jbc.M212355200]
103. Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 2005; 146: 2055-2059 [PMID: 15604213 DOI: 10.1210/en.2004-1174]
104. Green BD, Irwin N, Flatt PR. Pituitary adenylate cyclaseactivating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides 2006; 27: 1349-1358 [PMID: 16406202 DOI: 10.1016/j.peptides.2005.11.010]
105. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagonlike peptide-2. Am J Physiol 1997; 272: E1050-E1058 [PMID: 9227451 DOI: 10.1210/en.2003-0309]
106. Walsh NA, Yusta B, DaCambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology 2003; 144: 4385-4392 [PMID: 12960094]
107. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51: 141-147 [PMID: 18025295 DOI: 10.1161/HYPERTENSIONAHA. 107.096552]
108. Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpé S, De Meester I. Kinetic study of the processing by dipeptidylpeptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001; 507: 327-330 [PMID: 11696365 DOI: 10.1016/S0014-5793(01)02982-9]
109. Mentlein R, Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 1996; 17: 709-720 [PMID: 8804084 DOI: 10.1016/0196-9781(96)00066-6]
110. Hernanz A, Medina S, de Miguel E, Martín-Mola E. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept 2003; 115: 19-24 [PMID: 12873794 DOI: 10.1016/S0167-0115(03)00127-7]
111. Reinehr T, Roth CL, Enriori PJ, Masur K. Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity. J Pediatr Endocrinol Metab 2010; 23: 101-108 [PMID: 20432813 DOI: 10.1515/JPEM.2010.23.1-2.101]
112. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol 2007; 27: 430-437 [PMID: 17525828 DOI: 10.1007/ s10875-007-9093-z]
113. Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist KG. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009; 183: 3616-3624 [PMID: 19687096 DOI: 10.4049/jimmunol. 0804336]
114. Rai AK, Thakur CP, Kumar P, Mitra DK. Impaired expression of CD26 compromises T-cell recruitment in human visceral leishmaniasis. Eur J Immunol 2012; 42: 2782-2791 [PMID: 22806538 DOI: 10.1002/eji.201141912]
115. Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP, Detheux M, Parmentier M, De Meester I, Scharpé S, Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999; 162: 4903-4909 [PMID: 10202035]
116. Forssmann U, Stoetzer C, Stephan M, Kruschinski C, Skripuletz T, Schade J, Schmiedl A, Pabst R, Wagner L, Hoffmann T, Kehlen A, Escher SE, Forssmann WG, Elsner J, von Hörsten S. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 2008; 181: 1120-1127 [PMID: 18606664]
117. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpé S, Van Damme J, De Meester I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276: 29839-29845 [PMID: 11390394 DOI: 10.1074/jbc.M103106200]
118. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 2005; 11: 35-42 [PMID: 15591886 DOI: 10.1097/01.mcp.0000144502.50149.e0]
119. Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW. Decreased expression of T lymphocyte co-stimulatory molecule CD26 on invariant natural killer T cells in systemic lupus erythematosus. Immunol Invest 2009; 38: 350-364 [PMID: 19811413 DOI: 10.1080/08820130902770003]
120. Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, Chang JJ, Dore GJ, Price P, Visvanathan K, French M, Ruxrungtham K, Lewin SR. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199: 974-981 [PMID: 19231993 DOI: 10.1086/597276]
121. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-3561 [PMID: 11739156 DOI: 10.1182/blood.V98.13.3554]
122. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 2002; 72: 183-191 [PMID: 12101279]
123. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24 [PMID: 10588446 DOI: 10.1016/S0167-0115(99)00089-0]
124. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1794-R1802 [PMID: 18832087 DOI: 10.1152/ajpregu. 90616.2008]
125. Faidley TD, Leiting B, Pryor KD, Lyons K, Hickey GJ, Thompson DR. Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. Exp Biol Med (Maywood) 2006; 231: 1373-1378 [PMID: 16946406]
126. Nausch I, Mentlein R, Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler 1990; 371: 1113-1118 [PMID: 1982212 DOI: 10.1515/ bchm3.1990.371.2.1113]
127. Ohta N, Takahashi T, Mori T, Park MK, Kawashima S, Takahashi K, Kobayashi H. Hormonal modulation of prolyl endopeptidase and dipeptidyl peptidase IV activities in the mouse uterus and ovary. Acta Endocrinol (Copenh) 1992; 127: 262-266 [PMID: 1357903]
128. Rovenský J, Buc M, Lojda Z, Ruzicková M, Blazícková S, Rauová L, Mistina T, Vigas M, Lackovic V. Effect of domperidone-induced hyperprolactinemia on selected immune parameters in healthy women. Arch Immunol Ther Exp (Warsz) 1995; 43: 221-227 [PMID: 8744700]
129. Fujiwara H, Fukuoka M, Yasuda K, Ueda M, Imai K, Goto Y, Suginami H, Kanzaki H, Maeda M, Mori T. Cytokines stimulate dipeptidyl peptidase-IV expression on human luteinizing granulosa cells. J Clin Endocrinol Metab 1994; 79: 1007-1011 [PMID: 7962267 DOI: 10.1210/jc.79.4.1007]
130. Sakurada C, Sakurada S, Hayashi T, Katsuyama S, Tan-No K, Sakurada T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol 2003; 66: 653-661 [PMID: 12906930]
131. Rónai AZ, Király K, Szebeni A, Szemenyei E, Prohászka Z, Darula Z, Tóth G, Till I, Szalay B, Kató E, Barna I. Immunoreactive endomorphin 2 is generated extracellularly in rat isolated L4,5 dorsal root ganglia by DPP-IV. Regul Pept 2009; 157: 1-2 [PMID: 19540879 DOI: 10.1016/j.regpep.2009.06.006]
132. Király K, Szalay B, Szalai J, Barna I, Gyires K, Verbeken M, Rónai AZ. Intrathecally injected Ile-Pro-Ile, an inhibitor of membrane ectoenzyme dipeptidyl peptidase IV, is antihyperalgesic in rats by switching the enzyme from hydrolase to synthase functional mode to generate endomorphin 2. Eur J Pharmacol 2009; 620: 21-26 [PMID: 19695241 DOI: 10.1016/j.ejphar.2009.08.018]
133. Guieu R, Fenouillet E, Devaux C, Fajloun Z, Carrega L, Sabatier JM, Sauze N, Marguet D. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain Res 2006; 166: 230-235 [PMID: 16154213 DOI: 10.1016/ j.bbr.2005.08.003]
134. Busek P, Stremenová J, Krepela E, Sedo A. Modulation of substance P signaling by dipeptidyl peptidase-IV enzymatic activity in human glioma cell lines. Physiol Res 2008; 57: 443-449 [PMID: 17949241]
135. Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 151: 3049-3060 [PMID: 20444936 DOI: 10.1210/en.2010-0068]
136. Zhang XY, De Meester I, Lambeir AM, Dillen L, Van Dongen W, Esmans EL, Haemers A, Scharpé S, Claeys M. Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. J Mass Spectrom 1999; 34: 255-263 [PMID: 10226356 DOI: 10.1002/(SICI)1096-9888(199904)34]